Revitalist Signs its 9th Clinic Lease in Jacksonville, Florida

Share Post:

VANCOUVER, BC, November 30, 2021 – REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to formally announce it has signed a lease for its 9th psychedelic assisted psychotherapy (“PAP”) clinic located at 6871 Belfort Oaks Place, Jacksonville, Florida. The Jacksonville location will offer 6,865 square feet of space and 12 infusion rooms. The Jacksonville clinic is expected to open before December 31, 2021 and offer Revitalist’s full suite of treatments including IV ketamine infusions, vitamin infusions, medication infusions, intensive outpatient programs, ketamine assisted psychotherapy, Spravato, telemedicine therapy sessions, and transcranial magnetic stimulation. With 12 treatment rooms, the clinic can provide over 12,480 ketamine infusions to patients annually. The addition of the Jacksonville lease marks the ninth Revitalist clinic which will increase the total capacity at Revitalist to 60,657 square feet and 121 treatment rooms detailed below.

Kathryn Walker, CEO, commented “This facility will represent our eighth clinic operating in six different states. Johns Hopkins Medicine reports that mental health disorders account for several of the top causes of disability in established market economies, such as the U.S., and worldwide. Approximately 9.5% of American adults ages 18 and over, will suffer from a depressive illness each year. With eight clinics and counting, Revitalist expects to help combat this issue.”

ABOUT REVITALIST LIFESTYLE AND WELLNESS LTD.

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is a publicly traded company, headquartered in Knoxville, Tennessee, with seven clinics operating across the United States and expanding. Revitalist is dedicated to empowering individuals toward an improved quality of well-being through a combination of comprehensive care and futurecentric treatments provided by medical professionals, mental health experts, and chronic pain specialists. Since opening their first clinic in 2018, Revitalist has provided thousands of infusions for patients suffering from treatment-resistant conditions. Additionally, Revitalist offers a number of lifestyle optimization services and vitamin infusions that can bring anyone closer to total wellness.

Twitter: @RevitalistCorp
Facebook: @RevitalistLifestyleandWellnessLtd
Instagram: @RevitalistCorp
LinkedIn: @RevitalistLifestyleAndWellnessLtd

On Behalf of the Board
Kathryn Walker
Chief Executive Officer

For further information please contact:
Revitalist Lifestyle and Wellness Ltd.
Email: [email protected]
Tel: (865) 585-8414

Forward Looking Statements
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Revitalist to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.

Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Stay Connected

More Press Releases

Psychedelic Community Reacts To FDA Committee’s Critique Of Lykos’ MDMA Studies Guest Column | June 14, 2024 As told to Abby Proch, executive editor of